

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, ...
Q2 2026
Aug 6, 2026
Q1 2026
May 13, 2026
FY 2025
Feb 26, 2026
Q4 2025
Feb 26, 2026
Q3 2025
Nov 13, 2025